- Home
- IMRX vs FDMT Comparison
IMRX vs FDMT Comparison
Compare IMRX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- FDMT
- Stock Information
- Founded
- IMRX 2008
- FDMT 2013
- Country
- IMRX United States
- FDMT United States
- Employees
- IMRX N/A
- FDMT N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- FDMT Health Care
- Exchange
- IMRX Nasdaq
- FDMT Nasdaq
- Market Cap
- IMRX 232.9M
- FDMT 192.2M
- IPO Year
- IMRX 2021
- FDMT 2020
- Fundamental
- Price
- IMRX $8.07
- FDMT $6.66
- Analyst Decision
- IMRX Strong Buy
- FDMT Buy
- Analyst Count
- IMRX 4
- FDMT 9
- Target Price
- IMRX $13.75
- FDMT $30.63
- AVG Volume (30 Days)
- IMRX 1.3M
- FDMT 520.4K
- Earning Date
- IMRX 11-12-2025
- FDMT 11-12-2025
- Dividend Yield
- IMRX N/A
- FDMT N/A
- EPS Growth
- IMRX N/A
- FDMT N/A
- EPS
- IMRX N/A
- FDMT N/A
- Revenue
- IMRX N/A
- FDMT $33,000.00
- Revenue This Year
- IMRX N/A
- FDMT $8,572.97
- Revenue Next Year
- IMRX N/A
- FDMT N/A
- P/E Ratio
- IMRX N/A
- FDMT N/A
- Revenue Growth
- IMRX N/A
- FDMT N/A
- 52 Week Low
- IMRX $1.10
- FDMT $2.24
- 52 Week High
- IMRX $9.37
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- IMRX 69.91
- FDMT 53.43
- Support Level
- IMRX $7.82
- FDMT $6.60
- Resistance Level
- IMRX $8.85
- FDMT $7.21
- Average True Range (ATR)
- IMRX 0.75
- FDMT 0.42
- MACD
- IMRX 0.19
- FDMT -0.07
- Stochastic Oscillator
- IMRX 69.91
- FDMT 48.25
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.